Division of Neuroscience, National Institute on Aging, National Institutes of Health.
Ethn Dis. 2020 Nov 19;30(Suppl 2):705-708. doi: 10.18865/ed.30.S2.705. eCollection 2020.
The National Alzheimer's Project Act identifies the effective treatment and prevention of Alzheimer's by 2025 as an urgent public health mission. This priority is reflected in the recent increases in public funding that is accelerating Alzheimer's and related dementias research. Many drugs and clinical interventions are in rapid development, with the promising ones moving to clinical trials to be tested. There are currently more than 200 on-going clinical trials, seeking more than 270,000 participants, which will require screening of more than a million individuals. With the race to treatment, how inclusive will screenings be to ensure diversification of the citizens volunteering to become trial participants? Underrepresented groups are chronically under-enrolled in clinical research studies. This under-enrollment leads to conclusions about disease risk factors and processes without all the necessary data because the studies are not representative of all people and all life experiences.
《国家阿尔茨海默病计划法案》将 2025 年前有效治疗和预防阿尔茨海默病确定为一项紧迫的公共卫生任务。这一优先事项反映在最近增加的公共资金上,这些资金正在加速阿尔茨海默病和相关痴呆症的研究。许多药物和临床干预措施正在迅速发展,有前途的药物正在进入临床试验进行测试。目前有 200 多项正在进行的临床试验,正在招募超过 27 万名参与者,这将需要对超过 100 万人进行筛选。随着治疗的竞争,筛选将如何具有包容性,以确保参与试验的志愿者的多样化?代表性不足的群体在临床研究中一直被招募不足。这种招募不足导致了关于疾病风险因素和过程的结论,而没有所有必要的数据,因为这些研究不能代表所有人和所有生活经历。